HPV VLP Bioconjugates Patent, Inventprise, Inc
Summary
Inventprise, Inc. has published patent application US20260097109A1 covering immunogenic compositions and vaccines comprising HPV virus-like particle (VLP) bioconjugates. The application includes L2 protein conjugates and methods for treating or preventing HPV infection. Filed October 7, 2025, and published April 9, 2026.
What changed
Inventprise, Inc. has published a patent application for HPV virus-like particle bioconjugates, covering immunogenic compositions, vaccines, and conjugates comprising VLP compositions conjugated to HPV L2 proteins. The application includes methods for manufacturing and treating or preventing HPV infection.
Patent applications represent potential intellectual property that, if granted, would provide enforceable rights. Competitors in the HPV vaccine space should monitor this application's progress and assess freedom-to-operate implications if it proceeds to grant.
What to do next
- Monitor patent prosecution status
- Review patent claims for freedom-to-operate analysis
Archived snapshot
Apr 11, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HPV Virus-Like Particle Bioconjugates
Application US20260097109A1 Kind: A1 Apr 09, 2026
Assignee
Inventprise, Inc.
Inventors
Subhash V. Kapre
Abstract
This invention is directed to immunogenic composition, vaccines and conjugates comprising virus-lie particles (VLP) compositions conjugated to one or more L2 proteins of HPV. The invention further includes methods for the manufacture of immunogenic compositions and vaccines and methods for the treatment and/or prevention of HPV infection.
CPC Classifications
A61K 39/12 A61K 2039/5258 A61K 2039/6037 A61K 2039/6075
Filing Date
2025-10-07
Application No.
19352201
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.